Cross-Sector entity
Arbutus Biopharma is most often covered alongside Genevant Sciences, which appears in 3 of these 3 stories. Across a 169-day span, the pace is roughly 0.1 stories per week. The busiest single day carried 2. market-trends accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder.
3 verified stories tracked
Last mentioned: 5d ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 33 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Arbutus Biopharma is most often covered alongside Genevant Sciences, which appears in 3 of these 3 stories. Across a 169-day span, the pace is roughly 0.1 stories per week. The busiest single day carried 2. market-trends accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder. Each carries 2 original sources on average. This profile follows 3 Cross-Sector stories mentioning Arbutus Biopharma across the period from March 4, 2026 to August 19, 2026.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Arbutus Biopharma. Shared-story counts are live from our verified record — not editorial picks.
Settlement Reached
Moderna agrees to pay up to $2.25 billion to resolve all outstanding claims.
Claims Construction
Court rulings on patent definitions provide momentum for the plaintiffs.
Lawsuit Filed
Arbutus and Genevant sue Moderna for patent infringement in Delaware federal court.
Vaccine Launch
Moderna receives EUA for Spikevax, utilizing LNP technology for delivery.
Coinbase surged 11.2% on August 19, 2026, after CEO Brian Armstrong prepared to meet President Trump and Bitcoin rebounded toward $65,000. The CLARITY Act remains stuck in the Senate, leaving SEC and CFTC rulemaking as the near-term path. For crypto investors, this is a leveraged policy-plus-BTC-beta event.
Source: markets.financialcontent.com
Moderna has reached a landmark $2.25 billion settlement with Roivant Sciences and Arbutus Biopharma to resolve long-standing patent disputes over lipid nanoparticle technology used in its COVID-19 vaccine. The agreement provides a massive capital infusion for Roivant while removing a significant legal overhang for Moderna's future mRNA pipeline.
Moderna has agreed to pay Roivant Sciences up to $2.25 billion to settle long-standing patent infringement claims regarding the Lipid Nanoparticle (LNP) technology used in its COVID-19 vaccine. The settlement provides a massive capital windfall for Roivant and Arbutus Biopharma while removing a major legal risk for Moderna.
